Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Potek bolezni pri bolnicah s HER-2 pozitivnim rakom dojk
Authors:Ribnikar, Domen (Author)
Fink, Špela (Author)
Frković-Grazio, Snježana (Author)
Lešničar, Hotimir (Author)
Sadikov, Aleksander (Author)
Čufer, Tanja (Author)
Language:Slovenian
Tipology:1.01 - Original Scientific Article
Organisation:Logo OI - Institute of Oncology
Year of publishing:2008
COBISS_ID:25343193 Link is opened in a new window
UDC:616-006
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
URN:URN:NBN:SI:doc-JJWIMRX6
Note:Soavtorji: Š. Fink, S. Frković Grazio, H. Lešničar, A. Sadikov in T. Čufer; BSDOCID143369;
Views:2077
Downloads:502
Files:.pdf PDF - Presentation file, download (230,67 KB)
 
Journal:Onkologija
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Clinical course of HER-2 positive breast cancer patients
Abstract:Breast cancer is the most frequent cancer in women. The course and efficiency of breast cancer treatment are influenced by several factors. The expression of HER-2 protein and HER-2 gene is gaining in strength in breast cancer management. The aim of our study was to compare the course of HER-2 positive with HER-2 negative disease. In median time of 2.5 years DFS (disease-free-survival) of patients with HER-2 positive tumours was 76.1%, and 93.4% for patients with HER-2 negative disease. HER-2 status was the strongest prognostic factor for DFS (p

Archive

niGradiv

Back